About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

Delta-Fly Pharma, Inc.(4598) Summary

4598
TSE Growth
Delta-Fly Pharma, Inc.
502
JPY
-40
(-7.38%)
Apr 4, 3:30 pm JST
3.43
USD
Apr 4, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
PBR
7.09
Yield
ー%
Margin Trading Ratio
Stock Price
Apr 4, 2025
Opening Apr 4, 9:02 am
532 JPY 3.63 USD
Previous Close Apr 3
542 JPY 3.68 USD
High Apr 4, 9:02 am
540 JPY 3.69 USD
Low Apr 4, 1:56 pm
485 JPY 3.33 USD
Volume
773,700
Trading Value
0.39B JPY 2.68M USD
VWAP
506.73 JPY 3.47 USD
Minimum Trading Value
50,200 JPY 343 USD
Market Cap
4.88B JPY 0.03B USD
Number of Trades
1,296
Liquidity & Number of Trades
As of Apr 4, 2025
Liquidity
Slightly High
1-Year Average
786
1-Year High Dec 12, 2024
14,239
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 28, 2025 0 1,639,000
Mar 21, 2025 0 1,664,000
Mar 14, 2025 100 1,690,000 16900.00
Mar 7, 2025 0 1,801,100
Feb 28, 2025 0 1,727,300
Company Profile
Delta-Fly Pharma, Inc. is a bioventure company developing anticancer drugs. The company handles everything from research and development to manufacturing and sales.
Sector
Pharmaceuticals
Delta-Fly Pharma, Inc. is a bioventure company that consistently handles the entire process from research and development to manufacturing and sales of anticancer drugs. Using its proprietary "modular drug discovery" method, the company aims to create new anticancer drugs with an excellent balance of clinical efficacy and safety by combining existing anticancer active substances. With multiple development pipelines, the company is conducting clinical trials targeting recurrent and refractory acute myeloid leukemia, lung cancer, pancreatic cancer, and other conditions. Their business model is based on generating revenue through product sales, milestone payments, and royalty income by out-licensing sales rights to pharmaceutical companies. Focusing on licensing agreements with pharmaceutical companies, Delta-Fly Pharma has established an efficient research and development system by utilizing external resources.